Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amitriptyline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 8/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 6/20 | 0.97 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | ATM | Q13315 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 8/20 | 0.97 |
| ▸ | HTR2B | P41595 | 8/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.97 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.97 |
| ▸ | DRD2 | P14416 | 6/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 6/20 | 0.97 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amitriptyline SCHEMBL14937172 | 1.00 | SLC6A2 (1.00) | SLC6A2LMNAALDH1A1PMP22MEN1 | |
| Amitriptyline SCHEMBL41079 | 1.00 | SLC6A2 (1.00) | SLC6A2LMNAALDH1A1PMP22MEN1 | |
| Amitriptyline SCHEMBL14918734 | 0.98 | SLC6A2 (0.97) | SLC6A2LMNAALDH1A1PMP22MEN1 | |
| Amitriptyline SCHEMBL2877708 | 0.98 | SLC6A2 (1.00) | SLC6A2LMNAALDH1A1PMP22MEN1 | |
| Amitriptyline SCHEMBL7824 | 0.98 | SLC6A2 (1.00) | SLC6A2LMNAALDH1A1PMP22MEN1 | |
| Amitriptyline SCHEMBL29359365 | 0.98 | SLC6A2 (1.00) | SLC6A2LMNAALDH1A1PMP22MEN1 | |
| Amitriptyline SCHEMBL28299765 | 0.97 | SLC6A2 (0.97) | SLC6A2LMNAALDH1A1PMP22MEN1 | |
| Amitriptyline SCHEMBL7215255 | 0.97 | SLC6A2 (0.97) | SLC6A2LMNAALDH1A1PMP22MEN1 | |
| Amitriptyline SCHEMBL3055149 | 0.95 | SLC6A2 (0.94) | SLC6A2LMNAALDH1A1PMP22MEN1 | |
| Amitriptyline SCHEMBL8070446 | 0.90 | SLC6A2 (0.83) | SLC6A2LMNAALDH1A1PMP22MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 309 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3532092-B1 | IMMUNOGLOBULINS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2026-04-29 | — | — | EP | claimed |
| EP-4074729-B1 | AMYLIN ANALOGUES | ZEALAND PHARMA AS (DK) | 2026-04-15 | — | — | EP | claimed |
| EP-4271674-B9 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4043017-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-3781315-B1 | MICROFLUIDIC METHOD FOR SINGLE CELL ANALYSIS | HIFIBIO SAS (FR) | 2026-01-14 | — | — | EP | claimed |
| EP-4271672-B1 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-12-03 | — | — | EP | claimed |
| EP-4271674-B3 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-12-03 | — | — | EP | claimed |
| EP-4062917-B1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2025-12-03 | — | — | EP | claimed |
| EP-3914298-B1 | DEVICE FOR JOINT EXTRACTION OF A METAL CATION AND A TARGET MOLECULE | MEXBRAIN (FR) | 2025-11-12 | — | — | EP | claimed |
| EP-3787631-B1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | UNIV EMORY (US) | 2025-09-10 | — | — | EP | claimed |
| EP-3229023-B1 | METHOD FOR DETECTING AGGREGATE FORM OF AGGREGATE-FORMING POLYPEPTIDE | PEOPLEBIO INC (KR) | 2023-06-07 | — | — | EP | claimed |
| EP-3509573-B1 | PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF PEPTIDE | ANYA BIOPHARM INC (TW) | 2023-05-24 | — | — | EP | claimed |
| EP-2440184-B1 | DIKETOPIPERAZINE MICROPARTICLES WITH DEFINED SPECIFIC SURFACE AREAS | MANNKIND CORP (US) | 2023-04-05 | — | — | EP | claimed |
| EP-4125827-A1 | DMEH ENHANCER | LTS LOHMANN Therapie-Systeme AG (DE) | 2023-02-08 | — | — | EP | claimed |
| EP-3529251-B1 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA | NOVARTIS AG (CH) | 2022-10-05 | — | — | EP | claimed |
| EP-3587404-B1 | MICROCRYSTALLINE DIKETOPIPERAZINE COMPOSITIONS, METHODS FOR PREPARATION AND USE THEREOF | MANNKIND CORP (US) | 2022-07-13 | — | — | EP | claimed |
| EP-4019039-A1 | COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTABLE SOLUTION COMPRISING AT LEAST ONE HUMAN INSULIN A21G AND A GLUCAGON SUPPRESSOR WITH PRANDIAL ACTION | Adocia (FR) | 2022-06-29 | — | — | EP | claimed |
| EP-3411026-B1 | USE OF STIMULATORS OF SOLUBLE GUANYLATE CYCLASE FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) | CYCLERION THERAPEUTICS INC (US) | 2022-03-09 | — | — | EP | claimed |
| EP-3658115-B1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AT LEAST HUMAN INSULIN A21G AND A PRANDIAL ACTION GLUCAGON SUPPRESSOR | ADOCIA (FR) | 2022-02-23 | — | — | EP | claimed |
| EP-3016684-B1 | REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES | H LUNDBECK AS (DK) | 2022-02-23 | — | — | EP | claimed |